SL Science Holding Ltd AI Stock Analysis
Want to see SLBT full AI Analyst Report?
SL Science Holding Ltd (SLBT) AI Stock Analysis
SL Science Holding Ltd
(NASDAQ:SLBT)
The overall score is at the minimum of 37, reflecting a high-risk, distressed profile. The most significant factor is the company's rapidly deteriorating financial health, marked by an unsustainable cash burn rate, collapsing margins, and a swing to deep losses. This is compounded by extremely bearish technicals, with the stock in a severe downtrend and deeply oversold. The lack of profitability renders standard valuation metrics useless, offering no support. The company faces existential risks without immediate access to new capital.
SL Science Holding Ltd (SLBT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $405.09M
- Dividend Yield
- ―
- Average Volume (3M)
- 67.50K
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- 5.47
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 15
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
SL Science Holding Ltd Business Overview & Revenue Model
Company Description
SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company’s products include SL bio’s milk-derived exosome essence, SL bio’s tangerine-derived extract, and the MilkExo concentrate series. It also offers research...
SL Science Holding Ltd Financial Statement Overview
Summary
Financial performance is critically weak. The Income Statement (Score 18) shows collapsing revenues, gross margins falling to 35%, and a swing to a $3.8M net loss. The Cash Flow Statement (Score 10) reveals an unsustainable cash burn rate with -$2.2M in free cash flow. The Balance Sheet (Score 45) shows rapid equity erosion, though debt is low. The overall trajectory is deeply negative, with the company consuming its remaining resources.
Income Statement
18Very NegativeBalance Sheet
45NeutralCash Flow
10Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | ― | 2.20M | 3.36M | 878.97K |
| Gross Profit | ― | 775.06K | 1.93M | 738.01K |
| EBITDA | -1,602 | -3.74M | -1.15M | 134.02K |
| Net Income | -1,602 | -3.82M | -1.19M | 399.04K |
Balance Sheet | ||||
| Total Assets | 5.79M | 2.82M | 5.93M | 4.24M |
| Cash, Cash Equivalents and Short-Term Investments | 3.37M | 1.26M | 3.68M | 276.85K |
| Total Debt | 305.67K | 213.41K | 0 | 550.06K |
| Total Liabilities | 1.06M | 533.28K | 204.90K | 668.07K |
| Stockholders Equity | 4.73M | 2.28M | 5.73M | 3.57M |
Cash Flow | ||||
| Free Cash Flow | -450 | -2.23M | 272.19K | -2.64M |
| Operating Cash Flow | -134 | -1.91M | 280.16K | -2.45M |
| Investing Cash Flow | -316 | -319.69K | 123.28K | -182.98K |
| Financing Cash Flow | -614 | -879.14K | 3.07M | 2.86M |
SL Science Holding Ltd Peers Comparison
Overall Rating
INMB51Neutral
TVGN47.6Neutral
RNXT42Neutral
ABVC39Underperform- SLBT37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| INMB | 51Neutral | $34.05M | -1.66 | -81.71% | ― | -100.00% | 71.08% |
| TVGN | 48Neutral | $39.07M | -1.18 | 248.50% | ― | ― | 36.06% |
| RNXT | 42Neutral | $58.87M | -3.67 | -149.01% | ― | 199.14% | 12.75% |
| ABVC | 39Underperform | $26.76M | -4.50 | -41.67% | ― | -100.00% | 39.04% |
| SLBT | 37Underperform | $428.42M | 0.00 | -95.36% | ― | ― | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SLBT | SL Science Holding Ltd | 0.76 | -2.57 | -77.06% | |
| INMB | Inmune Bio | 1.05 | -0.37 | -26.06% | |
| ABVC | ABVC BioPharma, Inc. | 0.96 | -1.96 | -67.02% | |
| RNXT | Renovorx, Inc. | 1.16 | 0.41 | 54.67% | |
| TVGN | Tevogen Bio Holdings Inc. | 5.72 | -15.14 | -72.57% |
SL Science Holding Ltd Corporate Events
SL Science Holding Names Chin-Sheng Hung Chief Medical Officer After Ethan Shen Resigns
SL Science Holding Limited is a Taiwan-based issuer, but the release did not specify its industry, primary products or services, or market focus.On November 1, 2026, Dr. Ethan Shen resigned as a director and chief technology officer, and the board ac...
SL Science Holding Files Form 6-K Detailing First-Half 2026 Results
On October 26, 2026, SL Science Holding Limited filed a Form 6-K with the U.S. Securities and Exchange Commission, furnishing unaudited interim consolidated financial statements and management’s discussion and analysis for the six months ended June 3...
SL Science Holding Adopts Cayman Islands Governance Exemptions on Nasdaq
On September 24, 2026, SL Science Holding Limited filed a Form 6-K announcing that, as a Cayman Islands-incorporated foreign private issuer on Nasdaq, it has elected to follow certain home country corporate governance practices. The company confirmed...
SL Science Holding Discloses Resignation of Vice President of Finance
On August 24, 2026, SL Science Holding Limited’s vice president of finance, Johnson Lau, tendered his resignation to the board of directors, with the board accepting his departure effective August 31, 2026. The company stated that Lau’s resignation w...
SL Science Holding Ltd Switches Audit Firm to TAAD LLP in Late August 2026
On August 21, 2026, SL Science Holding Ltd appointed TAAD LLP as its new independent registered public accounting firm, following the dismissal of ARK Pro CPA & Co on August 20, 2026 after an evaluation process approved by the audit committee. The co...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 12, 2026